The “efficacy” statement might be a hint as to what might be presented at ESMO. Maybe they wanted to keep low key until then. Get more bank for their buck presenting in front of all the Global Oncos.
Ann: Imugene Advances to Phase 2 in Gastric Cancer Trial, page-84
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
-0.001(2.56%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.8¢ | 3.9¢ | 3.8¢ | $134.8K | 3.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 1738258 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 494405 | 4 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
